Zurcher Kantonalbank Zurich Cantonalbank Purchases 1,780 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) by 26.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,444 shares of the company’s stock after purchasing an additional 1,780 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Vir Biotechnology were worth $354,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in VIR. Macquarie Group Ltd. purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at about $26,000. Canton Hathaway LLC purchased a new stake in shares of Vir Biotechnology during the 4th quarter valued at about $107,000. Dupont Capital Management Corp purchased a new stake in shares of Vir Biotechnology during the 4th quarter valued at about $174,000. Rathbone Brothers plc purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at about $218,000. Finally, CIBC Asset Management Inc boosted its holdings in shares of Vir Biotechnology by 10.9% in the third quarter. CIBC Asset Management Inc now owns 5,213 shares of the company’s stock worth $227,000 after buying an additional 514 shares during the last quarter. Institutional investors and hedge funds own 71.47% of the company’s stock.

Vir Biotechnology stock opened at $21.46 on Friday. The stock has a market cap of $2.84 billion, a P/E ratio of 5.53, a PEG ratio of 0.56 and a beta of -0.97. Vir Biotechnology, Inc. has a 1 year low of $20.52 and a 1 year high of $58.00. The firm’s 50 day moving average price is $24.74 and its 200-day moving average price is $33.19.

Vir Biotechnology (NASDAQ:VIRGet Rating) last released its quarterly earnings data on Thursday, February 24th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $1.32. The firm had revenue of $812.75 million for the quarter, compared to analysts’ expectations of $622.90 million. Vir Biotechnology had a net margin of 48.26% and a return on equity of 57.20%. The company’s revenue for the quarter was up 46771.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.83) earnings per share. Sell-side analysts expect that Vir Biotechnology, Inc. will post 3.91 earnings per share for the current fiscal year.

VIR has been the topic of a number of research reports. Needham & Company LLC dropped their price objective on shares of Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, March 28th. Zacks Investment Research downgraded shares of Vir Biotechnology from a “buy” rating to a “hold” rating in a report on Thursday, March 3rd. Robert W. Baird raised shares of Vir Biotechnology from an “underperform” rating to a “neutral” rating and dropped their price objective for the stock from $36.00 to $28.00 in a report on Thursday, March 3rd. HC Wainwright lowered their price target on shares of Vir Biotechnology from $300.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, March 30th. Finally, TheStreet downgraded shares of Vir Biotechnology from a “c-” rating to a “d+” rating in a report on Monday, March 28th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $67.29.

In other Vir Biotechnology news, CEO George A. Scangos sold 10,024 shares of Vir Biotechnology stock in a transaction on Thursday, February 17th. The shares were sold at an average price of $31.93, for a total transaction of $320,066.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Ann M. Hanly sold 2,627 shares of Vir Biotechnology stock in a transaction on Wednesday, March 30th. The stock was sold at an average price of $26.24, for a total transaction of $68,932.48. The disclosure for this sale can be found here. Insiders sold 31,462 shares of company stock worth $1,001,473 in the last 90 days. 30.90% of the stock is currently owned by company insiders.

Vir Biotechnology Company Profile (Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Further Reading

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.